The 5th Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics 2020 is dedicated to current challenges, best practices and the inside view of the future of Antibodies.
The 5th Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics 2020 covers topics such as:
- Emerging discoveries, cutting-edge knowledge, tools, methods, and technologies to bring clinically safe and efficient Antibodies
- 360° view of Antibody from key industry players to leverage your business and scientific practice adoption
- Novel approaches and Antibody formats to accelerate Antibody therapeutics
The 5th Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics 2020 brings together attendees involved in:
- Manufacturing/CMC
- Antibody & Biologics Discovery /Development
- Molecular Biology
- Protein Engineering
- Antibody-drug conjugates (ADCs)
- Medicinal Chemistry
- Immunoconjugates
- Bioconjugates
- Maytansine
- Monoclonal antibodies (mAbs)
- Duocarmycin
- Tubulysins
- α-amanitin
- PBD-dimers
- Marine-based cytotoxins
- Topoisomerase inhibitors
- Peptide-drug conjugates
- Small-molecule drug conjugates
- Diabodies/Minibodies
- Nanoparticles/Nanobodies
- ADME
- PKPD
- Analytical & Formulation
- Toxicology
- Cancer
- Bioanalysis
- Hematology
- Oncology
- Biotherapeutics
- Antibody-based therapeutics
- Chemotherapeutics
- Immunotherapeutics